The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
Meta-Z is not a peptide product. It is not a sleep formula. It is an injectable lipotropic-amino acid blend in the tradition of the MIC shot, extended with additional metabolic support compounds. Understanding what it actually is determines what realistic outcomes to expect.
The MIC injection tradition originates from lipotropic injection protocols developed in bariatric and weight loss medicine. 'Lipotropic' refers to compounds that support or enhance the metabolism of fat — specifically, compounds that prevent abnormal or excessive fat accumulation in the liver and support hepatic fat processing. Methionine, Inositol, and Choline are the three core lipotropic agents in the original MIC formula. Each has a role in one-carbon metabolism, phospholipid synthesis, or hepatic lipid export. They have been administered as intramuscular or subcutaneous injections in weight management clinics for decades, typically weekly or bi-weekly.
Meta-Z extends this framework significantly. To the MIC core, Peptide Partners adds: L-Carnitine (the rate-limiting factor in fatty acid transport into mitochondria for beta-oxidation); L-Arginine (nitric oxide precursor; cardiovascular support; insulin sensitivity); Taurine (bile acid conjugation; cardiovascular function; exercise performance); Leucine (the primary mTOR-activating branched-chain amino acid; lean mass support; protein synthesis signaling); Alpha-Lipoic Acid (universal antioxidant; glucose transporter upregulation; mitochondrial cofactor); and Methylcobalamin B12 (essential methylation cofactor; energy metabolism; neurological function). The combination addresses energy production, fat metabolism, antioxidant defense, and metabolic signaling from multiple complementary angles.
Each individual ingredient in Meta-Z has meaningful independent evidence. The specific combination as formulated has no clinical trial.
Grade B evidence exists for individual component applications: L-Carnitine weight management and fat oxidation support (multiple RCTs; systematic reviews; best evidence in L-carnitine-deficient populations and elderly); Alpha-Lipoic Acid diabetic neuropathy and glucose metabolism (multiple Phase 2/3 trials in T2D); Choline liver health and NAFLD (controlled trials; essential nutrient evidence); Inositol PCOS and metabolic syndrome (RCTs; Grade B for those specific indications); Methylcobalamin neuropathy and B12 deficiency (Grade A for deficiency treatment); L-Arginine cardiovascular and ED (multiple RCTs; Cochrane reviews); Taurine exercise performance (2021 meta-analysis: significant benefit across multiple performance metrics). The combination as a specific injectable blend: Grade E. Peptide Partners lists independent analysis as 'pending' for this product specifically.
Ingredient
Dose/mL
Primary Function
Key Mechanism
Methylcobalamin (B12)
1 mg
Methylation cofactor; energy; neurological; B12 deficiency treatment
A (B12 deficiency); B (metabolic enhancement)
Methyl donor in one-carbon metabolism; cofactor for methionine synthase and methylmalonyl-CoA mutase; critical for myelin synthesis and nerve function; deficiency causes neuropathy and macrocytic anemia
Methionine
50 mg
Essential sulfur amino acid; SAM-e precursor; liver lipid export; one-carbon metabolism
B (hepatic lipid metabolism; individual component trials)
Converted to S-adenosylmethionine (SAM-e) — universal methyl donor; supports phosphatidylcholine synthesis for VLDL assembly and hepatic fat export; methionine cycle substrate
Inositol
100 mg
Second messenger; phosphatidylinositol signaling; insulin sensitization; liver fat reduction
B (insulin resistance, PCOS, NAFLD RCTs)
Component of phosphatidylinositol — critical membrane phospholipid and second messenger scaffold; PI3K signaling (insulin pathway); clinical evidence for metabolic syndrome, PCOS, NAFLD
Choline Bitartrate
400 mg
Phosphatidylcholine synthesis; hepatic VLDL assembly; acetylcholine precursor
B (liver health, cognitive, pregnancy)
Rate-limiting substrate for phosphatidylcholine (PC) synthesis; PC is required for VLDL assembly and hepatic fat export; without adequate choline, fat accumulates in liver (NAFLD); also acetylcholine precursor (neuromuscular function, memory)
Taurine
50 mg
Bile acid conjugation; antioxidant; cardiovascular; exercise performance
B (cardiac, exercise, metabolic RCTs)
Most abundant intracellular amino acid; bile acid conjugation in liver (taurine-conjugated bile acids); antioxidant (sulfonic acid group scavenges ROS); osmoregulation; cardiac contractility; exercise performance meta-analysis 2021 showed significant benefit
Leucine
20 mg
mTOR activation; protein synthesis signaling; lean mass maintenance
B (muscle protein synthesis, aging, sarcopenia)
Primary mTOR (mechanistic target of rapamycin) activating BCAA; unique among BCAAs for mTOR pathway activation that drives muscle protein synthesis; clinically relevant for muscle preservation in caloric restriction or aging contexts
L-Carnitine
500 mg
Fatty acid transport into mitochondria; beta-oxidation; energy; weight management
B (multiple RCTs in weight management, cardiovascular, exercise)
Rate-limiting factor for long-chain fatty acid transport across inner mitochondrial membrane via carnitine acyltransferase (CAT) system; without sufficient carnitine, fatty acids cannot enter mitochondria for beta-oxidation; highest dose component in Meta-Z
L-Arginine
200 mg
Nitric oxide precursor; vascular function; GH secretagogue; wound healing
B (cardiovascular, ED, wound healing RCTs)
Direct precursor to nitric oxide (NO) via nitric oxide synthase (NOS); NO drives vasodilation and blood flow; also a growth hormone secretagogue at high doses (not therapeutic in this formulation dose); urea cycle component
Alpha-Lipoic Acid (ALA)
25 mg
Universal antioxidant; GLUT4 translocation; mitochondrial cofactor; neuroprotection
B (diabetes, neuropathy, metabolic RCTs)
Cofactor for pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase (TCA cycle); reduces oxidized forms of Vitamins C and E and glutathione (universal antioxidant regenerator); GLUT4 translocation (improves peripheral glucose uptake); neuroprotection
The original MIC formula addresses hepatic fat metabolism from three angles: Methionine provides the methyl groups (via SAM-e) needed for phosphatidylcholine synthesis and VLDL particle assembly. Choline is the direct substrate for phosphatidylcholine (the primary phospholipid in VLDL particles that export fat from the liver to peripheral tissues). Inositol supports phosphatidylinositol signaling and insulin pathway function, improving the metabolic context in which fat is processed. Together, these three ensure adequate substrate and signaling for hepatic fat export rather than hepatic fat accumulation. Clinical applications in weight management clinics: supporting liver function during caloric restriction; reducing hepatic fat in NAFLD protocols; improving metabolic efficiency during fat loss phases.
The four amino acids address energy production, fat transport, and lean mass preservation: L-Carnitine (500 mg/mL — the highest-dosed ingredient) enables fatty acid entry into mitochondria for beta-oxidation; without adequate carnitine, dietary and stored fat cannot be efficiently burned. L-Arginine supports vascular NO production, improving blood flow and nutrient delivery; at the doses in Meta-Z it also contributes to urea cycle function and wound healing signaling. Leucine activates mTOR-driven muscle protein synthesis, providing an anabolic signal that helps preserve lean mass during caloric restriction. Taurine supports bile acid conjugation (facilitating fat absorption from the gut), antioxidant defense, and cardiovascular function — important during high-output exercise and metabolic stress.
Methylcobalamin B12 is the nerve-active form of B12; it is the preferred form over cyanocobalamin for neurological support and methylation efficiency. At 1 mg/mL, this is a supraphysiological dose — consistent with injectable B12 protocols used for B12 deficiency treatment. The injection route bypasses gastrointestinal absorption (the intrinsic factor/parietal cell system that limits oral B12 absorption) and guarantees bioavailability. Alpha-Lipoic Acid at 25 mg/mL rounds out the formula as the mitochondrial cofactor and universal antioxidant: it regenerates Vitamins C and E from their oxidized forms, supports TCA cycle enzyme function, and promotes GLUT4 translocation to improve glucose disposal.
Meta-Z contains 2% Lidocaine at 0.1% concentration in the final formulation. Lidocaine is a local anesthetic that reduces injection site pain — relevant because several of the Meta-Z components (Methionine, Choline, L-Carnitine in particular) can be irritating when injected. Lidocaine at this concentration is standard practice in many injectable blend formulations. Clinical consideration: users with known lidocaine or amide-type local anesthetic allergy should not use Meta-Z. Users taking other medications that affect cardiac conduction should note the lidocaine content (though at this concentration systemic absorption is minimal from a single subcutaneous dose).
Meta-Z is used in the community primarily in the context of: body recomposition protocols (fat loss + lean mass preservation simultaneously); metabolic support during caloric restriction; energy and fatigue management during intense training periods; hepatic support when other injectable protocols are running. Typical community use: 0.5-2 mL subcutaneously or intramuscularly 1-3 times per week; most users inject 1-2 mL. Storage: room temperature (per Peptide Partners label); no refrigeration required. 10mL vials available; 50mL kit available.
Injection considerations: the lidocaine content means injections are notably less painful than many peptide injections; the high Choline content (400 mg/mL) can cause a fishy body odor as choline is metabolized to trimethylamine (TMA) and then TMAO; users sensitive to this should use lower doses or higher injection frequency with lower per-injection volume. The L-Carnitine at 500 mg/mL means even a 1mL injection delivers 500mg L-Carnitine — within the clinically studied range (500-2000mg/day in most L-Carnitine RCTs).
Meta-Z contains no pharmacologically defined peptides. Amino acids are building blocks of peptides but are not peptides themselves. This is an amino acid/vitamin/cofactor injectable blend. It belongs in the same document for completeness because it is a Peptide Partners product commonly purchased alongside genuine peptide products, but it has a fundamentally different compound class and evidence framework.
Meta-Z has zero sleep-specific components. It contains no DSIP, no melatonin, no GABA, no theanine, no sleep-modulating peptide. The 'sleep stack' description was an error in the Notion catalog that has been corrected. Users seeking sleep support should see the DSIP chapter (pbdsipv4) or the GH Stack chapter (GH Stack improves slow-wave sleep via GHRH pathway).
Injectable delivery bypasses GI absorption, improving bioavailability for components that have poor oral bioavailability (B12, Choline to some extent). For components with good oral bioavailability (L-Carnitine, L-Arginine, ALA), the injection route provides certainty of dosing but not necessarily dramatically superior clinical outcomes. The dose per mL is high, but the volume per injection (0.5-2 mL) determines total dose — a 1mL injection delivers 500mg L-Carnitine, which is within the oral supplementation range for L-Carnitine clinical trials.
Meta-Z is a well-formulated lipotropic injectable blend with individually evidence-supported components targeting fat metabolism, energy production, antioxidant defense, and lean mass support. It is not a peptide product and not a sleep product.
— End of Meta-Z —
THE PEPTIDE BIBLE | Meta-Z | For Research & Educational Purposes Only
Meta-Z: Peptide Partners energy-focused lipotropic proprietary injectable blend (Manufacturer ID: DF05; Batch MZ20250726). NOT a peptide. NOT a sleep product. CLASSIFICATION: Lipotropic/amino acid/metabolic injection blend. INGREDIENTS (per mL): B12 (Methylcobalamin) 1mg; Methionine 50mg; Inositol 100mg; Choline Bitartrate 400mg; Taurine 50mg; Leucine 20mg; L-Carnitine 500mg; L-Arginine 200mg; Alpha-Lipoic Acid 25mg. Also: 2% Benzoic Acid (preservative); 2% Lidocaine 0.1% (injection pain reduction); sterile water. Storage: room temperature. THREE FUNCTIONAL GROUPS: (1) MIC LIPOTROPIC CORE: Methionine (SAM-e precursor; VLDL/fat export substrate) + Inositol (PI signaling; insulin pathway; NAFLD/PCOS evidence) + Choline (PC synthesis; VLDL assembly; hepatic fat export; acetylcholine precursor). (2) AMINO ACID SUPPORT: L-Carnitine 500mg (fatty acid transport into mitochondria; beta-oxidation rate-limiting; highest dose) + L-Arginine 200mg (NO synthesis; vascular; GH secretagogue at high dose) + Leucine 20mg (mTOR activation; muscle protein synthesis; lean mass) + Taurine 50mg (bile acid conjugation; antioxidant; cardiovascular; exercise performance). (3) COFACTORS: B12 Methylcobalamin 1mg (nerve-active form; methylation; energy; bypasses GI for guaranteed bioavailability) + Alpha-Lipoic Acid 25mg (TCA cycle cofactor; universal antioxidant regenerator; GLUT4 translocation; neuroprotection). EVIDENCE: individual components Grade B (multiple RCTs); specific combination Grade E (no combination trial; Peptide Partners 'independent analysis pending'). COMMUNITY USE: 0.5-2 mL SubQ or IM 1-3x/week; body recomposition, fat loss support, energy, hepatic support. CONTAINS LIDOCAINE: less painful injection; amide anesthetic allergy consideration. HIGH CHOLINE: may cause fishy body odor (TMA metabolite). NOT a peptide chapter in the pharmacological sense — included for completeness as a Peptide Partners product in community use.
A Structural Modification of Semax With No Published Studies of Its Own. Being Sold as 'The Most Potent Semax Analog.' Every Claim Belongs to Its Parent Compound.
The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.
Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.